NCT02209051

Brief Summary

The primary goal of the study is to demonstrate the increased rate of complete wound closure by AMNIOEXCEL® compared to routine care in patients with chronic diabetic foot ulcers

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
29

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2014

Geographic Reach
1 country

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2014

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 31, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 5, 2014

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
Last Updated

December 2, 2017

Status Verified

November 1, 2017

Enrollment Period

1.1 years

First QC Date

July 31, 2014

Last Update Submit

November 30, 2017

Conditions

Keywords

Diabetic Foot UlcersAMNIOEXCELWagner Grade 1 or 2 foot ulcersWoundFoot healthUlcerFoot UlcerDiabetic FootFoot DiseasesSkin DiseasesLeg UlcerSkin UlcerDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesDiabetic Neuropathies

Outcome Measures

Primary Outcomes (1)

  • Proportion of patients with complete wound closure (i.e. complete skin re-epithelialization without drainage or dressing requirements) at 6 weeks after initiation of study treatment

    8 weeks

Secondary Outcomes (4)

  • Time to complete wound closure of the target ulcer

    8 weeks

  • Rate of wound closure

    8 Weeks

  • Incidence, severity and type of adverse events

    8 Weeks

  • Changes in Quality of Life assessment

    8 Weeks

Study Arms (2)

AMNIOEXCEL

ACTIVE COMPARATOR

Human Amniotic Membrane Allograft

Other: AMNIOEXCELOther: Standard of Care, Diabetic Foot Ulcers

Standard of Care, Diabetic Foot Ulcers

ACTIVE COMPARATOR

Advanced wound care dressings and offloading of wound.

Other: Standard of Care, Diabetic Foot Ulcers

Interventions

Application of AMNIOEXCEL every 1-2 weeks for a period of 6 weeks or until wound closure, whichever is sooner.

AMNIOEXCEL

Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure

AMNIOEXCELStandard of Care, Diabetic Foot Ulcers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • an ambulatory person at least 18 years of age at the time of informed consent.
  • type 1 or type 2 diabetes mellitus.
  • glycosylated hemoglobin (HbA1c) of ≤12%
  • at least one wound that is/has:
  • Wagner grade 1 or superficial 2 (without bone, tendon or joint exposure),
  • duration of at least 1 month,
  • no clinical signs of infection or osteomyelitis,
  • between 1cm2 and 25cm2 in area,
  • per original protocol, closed \<20% in area during the Screening Period; per Amendment #1, closed \<30% in area during Screening and
  • located on the foot, distal to malleoli.
  • adequate circulation to the affected extremity
  • serum creatinine of \<3.0mg/dl.

You may not qualify if:

  • participated in another clinical trial within 30 days prior to consent,
  • Active Charcot deformity of the study foot (i.e. erythematous, warm, edematous and actively remodeling)
  • receiving radiation or chemotherapy of any kind,
  • known or suspected malignancy of current ulcer,
  • pregnant or breast feeding,
  • an active malignant disease,
  • receiving hemo- or peritoneal dialysis,
  • sickle cell anemia or Raynaud's syndrome,
  • diagnosis of autoimmune connective tissue disease,
  • received a biologic agent, growth factor, xenograft or skin equivalent in the 30 days prior to consent,
  • exposed bone, tendon or joint capsule in the study ulcer,
  • currently receiving antibiotics (for any reason), or
  • taking medications considered to be immune system modulators.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Associated Foot and Ankle Specialists, LLC

Phoenix, Arizona, 85015, United States

Location

Center for Clinical Research, Inc.

Castro Valley, California, 94546, United States

Location

Pacific Wound Center

Stockton, California, 95204, United States

Location

First Coast Cardiovascular Institute

Jacksonville, Florida, 32216, United States

Location

Barry University Clinical Research

North Miami Beach, Florida, 33169, United States

Location

Beth Israel Deaconess Hospital - Plymouth

Plymouth, Massachusetts, 02360, United States

Location

Duke University

Durham, North Carolina, 27710, United States

Location

Wayne Memorial Hospital

Goldsboro, North Carolina, 27533, United States

Location

Related Publications (1)

  • Snyder RJ, Shimozaki K, Tallis A, Kerzner M, Reyzelman A, Lintzeris D, Bell D, Rutan RL, Rosenblum B. A Prospective, Randomized, Multicenter, Controlled Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer. Wounds. 2016 Mar;28(3):70-7.

MeSH Terms

Conditions

Diabetic FootWounds and InjuriesUlcerFoot UlcerFoot DiseasesSkin DiseasesLeg UlcerSkin UlcerDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesDiabetic Neuropathies

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Skin and Connective Tissue DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsMusculoskeletal DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 31, 2014

First Posted

August 5, 2014

Study Start

July 1, 2014

Primary Completion

August 1, 2015

Study Completion

August 1, 2015

Last Updated

December 2, 2017

Record last verified: 2017-11

Locations